VANLANDINGHAM JACOB PH.D 4
4 · Odyssey Health, Inc. · Filed Oct 19, 2022
Insider Transaction Report
Form 4
VANLANDINGHAM JACOB PH.D
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-10-14$0.32/sh+1,000,000$318,000→ 2,100,000 totalExercise: $0.32Exp: 2032-10-13→ Common Stock (1,000,000 underlying)
Footnotes (1)
- [F1]Vesting Schedule 250,000 upon signing; 250,000 upon an IND being approved by the FDA for Phase 2; 250,000 upon a listing on a national exchange (Nasdaq, NYSE); and 250,000 one year from Effective Date.